1.00
+0.0314(+3.26%)
Currency In USD
| Previous Close | 0.96 |
| Open | 0.92 |
| Day High | 1.04 |
| Day Low | 0.92 |
| 52-Week High | 21.09 |
| 52-Week Low | 0.26 |
| Volume | 1.35M |
| Average Volume | 16.71M |
| Market Cap | 174.35M |
| PE | 2.85 |
| EPS | 0.35 |
| Moving Average 50 Days | 1.48 |
| Moving Average 200 Days | 1.4 |
| Change | 0.03 |
If you invested $1000 in Tevogen Bio Holdings Inc. (TVGN) since IPO date, it would be worth $100.2 as of December 21, 2024 at a share price of $0.996. Whereas If you bought $1000 worth of Tevogen Bio Holdings Inc. (TVGN) shares 1 year ago, it would be worth $90.14 as of December 21, 2024 at a share price of $0.996.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Tevogen Bio Strengthens Robust IP Portfolio With Filing of Predictive AI Patent, With the Goal to Establish a Blueprint to Unlock the Full Potential of T Cell Therapies and Accelerate AI Integration to Advance Its Bold Growth Agenda
GlobeNewswire Inc.
Dec 19, 2024 1:30 PM GMT
WARREN, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat in
Tevogen Bio to Host Panel “Pioneering the Economics of Health: Balancing Access and Outcomes” During the 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Dec 17, 2024 6:32 PM GMT
WARREN, N.J., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat in
Tevogen Bio to Attend the 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Dec 10, 2024 8:13 PM GMT
WARREN, N.J., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat in